The effect of dexamethasone on treatment outcomes in patients with cerebral contusion and comorbid novel coronavirus infection (COVID-19)
https://doi.org/10.24884/1607-4181-2025-32-2-92-99
Abstract
Introduction. The problem of treating cerebral contusions in combination with a novel coronavirus infection is highly relevant in modern medicine and holds significant socio-economic importance.
Methods and materials. During the study period (January 2021 – January 2023), 185 patients aged 18 to 80 years (median 38.5 years) with verified cerebral contusions (subarachnoid hemorrhage, contusion-hemorrhagic foci, subdural and epidural hematomas, traumatic intracerebral hematomas) confirmed by CT scans, and a diagnosis of «novel coronavirus infection» verified via clinical, laboratory, and instrumental data (PCR swab for SARS-CoV-2, chest CT findings), were examined at the St. Petersburg State Budgetary Healthcare Institution «Alexandrovskaya Hospital».
Results. The administration of glucocorticoids in patients with moderate to severe cerebral contusions combined with COVID-19 reduces hypoxia, cerebral edema, and consequently shortens the regression time of generalized and focal neurological symptoms. A reduction in hospitalization duration was observed. To date, this method can be effectively used in treating patients with traumatic brain injury (TBI) and COVID-19. The approach is promising but requires further randomized studies.
Conclusion. Dexamethasone reduces mortality and accelerates recovery in patients with cerebral contusions combined with COVID-19.
About the Authors
A. S. Sosnovski
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Sosnovski Aleksander S., Postgraduate Student
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
A. D. Kanarsky
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Kanarsky Alexandr D., Neurosurgeon, Postgraduate Student
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
V. Yu. Cherebillo
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Cherebillo Vladislav Yu., Dr. Sci. (Med.), Professor, Head of the Department of Neurosurgery
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
M. Yu. Kurnukhina
Pavlov University
Russian Federation
Competing Interests:
Russian Federation
Kurnukhina Maria Yu., Cand. Sci. (Med.), Senior Laboratory Assistant at the Department of Neurosurgery
6-8, L’va Tolstogo str., Saint Petersburg, 197022
Competing Interests:
Authors declare no conflict of interest.
References
1. Carney N., Totten A. M., O’Reilly C. et al. Guidelines for the management of severe traumatic brain injury, fourth edition // Neurosurgery. 2017;80(1):6–15. http://doi.org/10.1227/NEU.0000000000001432.
2. Parfenov V. E., Samokhvalov I. M., Svistov D. V. et al. Modern approaches to the treatment of gunshot wounds to the head caused by non-lethal kinetic (traumatic) weapons // Neurosurgery. 2011;(3):52–57. (In Russ.).
3. Makarova E. V., Tyurikova L. V., Lyubavina N. A. The use of systemic corticosteroids in new coronavirus infection (from the perspective of international and Russian guidelines) // Medical Almanac. 2021;1(66):74–82. (In Russ.).
4. Interim guidelines: Prevention, diagnosis, and treatment of new coronavirus infection (COVID-19). Version 18 (2023). (In Russ.). URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/064/610/original/%D0%92%D0%9C%D0%A0_COVID-19_V18.pdf (accessed: 20.06.2025).
5. Manivannan S., Sharouf F., Mayo I. et al. Management of neurotrauma during COVID-19: a single centre experience and lessons for the future // Brain Inj. 2021;35(8):957–963. http://doi.org/10.1080/02699052.2021.1934731.
6. Lester A., Leach P., Zaben M. The Impact of the COVID-19 Pandemic on Traumatic Brain Injury Management: Lessons Learned Over the First Year // World Neurosurg. 2021;156:28–32. http://doi.org/10.1016/j.wneu.2021.09.030.
7. Kanarsky A. D., Sosnovsky A. S., Cherebillo V. Yu., Kurnukhina M. Yu. The use of anticoagulants in patients with traumatic brain injury, intracranial hematomas, and concomitant COVID-19 // Bulletin of Neurology, Psychiatry, and Neurosurgery. 2023;(7). (In Russ.). UDC: 616.8-007. http://doi.org/10.33920/med-01-2307-09.
8. Landyshev Yu. S. Mechanisms of action and main therapeutic effects of glucocorticoids // Amur Medical Journal. 2014;(1):10–29. (In Russ.).
9. RECOVERY Collaborative Group, Horby P., Lim W. S. et al. Dexamethasone in Hospitalized Patients with Covid-19 // N Engl J Med. 2021;384(8):693–704. http://doi.org/10.1056/NEJMoa2021436.
10. Sorrells S. F., Sapolsky R. M. An inflammatory review of glucocorticoid actions in the CNS // Brain Behav Immun. 2007;21(3):259–72. http://doi.org/10.1016/j.bbi.2006.11.006. PMID: 17194565; PMCID: PMC1997278.
11. Edwards P., Arango M., Balica L. et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury – outcomes at 6 months // The Lancet. 2005;365(9475):1957–1959. http://doi.org/10.1016/S0140-6736(05)66552-X.
12. Alderson P., Roberts I. Corticosteroids for acute traumatic brain injury // Cochrane Database of Systematic Reviews. 2005;(1):CD000196. http://doi.org/10.1002/14651858.CD000196.pub2.
13. The Writing Committee for the REMAP-CAP Investigators. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial // JAMA. 2020;324(13):1317–1329. http://doi.org/10.1001/jama.2020.17022.
Review
For citations:
Sosnovski A.S., Kanarsky A.D., Cherebillo V.Yu., Kurnukhina M.Yu. The effect of dexamethasone on treatment outcomes in patients with cerebral contusion and comorbid novel coronavirus infection (COVID-19). The Scientific Notes of the Pavlov University. 2025;32(2):92-99. (In Russ.) https://doi.org/10.24884/1607-4181-2025-32-2-92-99
Views:
6
Email this article 